These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 21187788)

  • 1. The direct and indirect cost burden of acute coronary syndrome.
    Johnston SS; Curkendall S; Makenbaeva D; Mozaffari E; Goetzel R; Burton W; Maclean R
    J Occup Environ Med; 2011 Jan; 53(1):2-7. PubMed ID: 21187788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The economic burden of acute coronary syndromes for employees and their dependents: medical and productivity costs.
    Page RL; Ghushchyan V; Gifford B; Read RA; Raut M; Crivera C; Naim AB; Damaraju CV; Nair KV
    J Occup Environ Med; 2013 Jul; 55(7):761-7. PubMed ID: 23787565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs of payment in Thai acute coronary syndrome patients.
    Moleerergpoom W; Kanjanavanit R; Jintapakorn W; Sritara P
    J Med Assoc Thai; 2007 Oct; 90 Suppl 1():21-31. PubMed ID: 18431883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct healthcare costs and resource consumption after acute coronary syndrome: a real-life analysis of an Italian subpopulation.
    Roggeri DP; Roggeri A; Rossi E; Cinconze E; De Rosa M; Maggioni AP;
    Eur J Prev Cardiol; 2014 Sep; 21(9):1090-6. PubMed ID: 23515447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost of care for new versus recurrent acute coronary syndrome patients.
    Shetty S; Halpern R; McCollam PL
    J Med Econ; 2008; 11(1):81-99. PubMed ID: 19450112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic consequences of ACS-related rehospitalizations in the US.
    Berenson K; Ogbonnaya A; Casciano R; Makenbaeva D; Mozaffari E; Lamerato L; Corbelli J
    Curr Med Res Opin; 2010 Feb; 26(2):329-36. PubMed ID: 19968457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health care resource utilization and costs associated with nonfatal major adverse cardiovascular events.
    Korsnes JS; Davis KL; Ariely R; Bell CF; Mitra D
    J Manag Care Spec Pharm; 2015 Jun; 21(6):443-50. PubMed ID: 26011546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of hospitalization and follow-up care costs among patients hospitalized with ACS treated with a stent and clopidogrel.
    Chastek B; Riedel AA; Wygant G; Hauch O
    Curr Med Res Opin; 2009 Dec; 25(12):2845-52. PubMed ID: 19831706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resource consumption and healthcare costs of acute coronary syndrome: a retrospective observational administrative database analysis.
    Roggeri A; Gnavi R; Dalmasso M; Rusciani R; Giammaria M; Anselmino M; Roggeri DP
    Crit Pathw Cardiol; 2013 Dec; 12(4):204-9. PubMed ID: 24240551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic Therapy and Direct Medical Costs in Patients with Acute Coronary Syndrome in Shanghai, China.
    Guo JJ; Chen Y; Du W; Peng H; Wang R; Xia Y; Xin P; Wigle PR; Papadimitropoulos EA
    Value Health Reg Issues; 2016 May; 9():93-98. PubMed ID: 27881268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacy cost sharing, antiplatelet therapy utilization, and health outcomes for patients with acute coronary syndrome.
    Philipson TJ; Mozaffari E; Maclean JR
    Am J Manag Care; 2010 Apr; 16(4):290-7. PubMed ID: 20394466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coronary artery bypass graft surgery in acute coronary syndrome: incidence, cost impact, and acute clopidogrel interruption.
    Johnston SS; Bell K; Gdovin J; Jing Y; Graham J
    Hosp Pract (1995); 2012 Feb; 40(1):15-23. PubMed ID: 22406879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of high-cost hospitalization in the treatment of acute coronary syndrome in Asia: findings from EPICOR Asia.
    Jan S; Lee SW; Sawhney JPS; Ong TK; Chin CT; Kim HS; Krittayaphong R; Nhan VT; Pocock SJ; Vega AM; Hayashi N; Huo Y
    BMC Cardiovasc Disord; 2018 Jul; 18(1):139. PubMed ID: 29973147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic burden of illness of acute coronary syndromes: medical and productivity costs.
    Zhao Z; Winget M
    BMC Health Serv Res; 2011 Feb; 11():35. PubMed ID: 21314995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Morbi-mortality and use of recourses after acute coronary syndrome in a Spanish population].
    Sicras-Mainar A; Fernández de Bobadilla J; Navarro-Artieda R; Martín I; Varela-Moreno C
    Rev Clin Esp; 2011 Dec; 211(11):560-71. PubMed ID: 22088667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic impact of angina after an acute coronary syndrome: insights from the MERLIN-TIMI 36 trial.
    Arnold SV; Morrow DA; Lei Y; Cohen DJ; Mahoney EM; Braunwald E; Chan PS
    Circ Cardiovasc Qual Outcomes; 2009 Jul; 2(4):344-53. PubMed ID: 20031860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of influenza vaccination in patients with acute coronary syndrome in Korea.
    Suh J; Kim B; Yang Y; Suh DC; Kim E
    Vaccine; 2017 May; 35(21):2811-2817. PubMed ID: 28427844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
    Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
    J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge.
    Lee HY; Cooke CE; Robertson TA
    J Manag Care Pharm; 2008 Apr; 14(3):271-80. PubMed ID: 18439049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total first-year costs of acute coronary syndrome in a managed care setting.
    Etemad LR; McCollam PL
    J Manag Care Pharm; 2005 May; 11(4):300-6. PubMed ID: 15871640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.